香雪製藥(300147.SZ):上半年淨利預增140%-170%
格隆匯6月5日丨香雪製藥(300147.SZ)披露2020年半年度業績預告,預計歸屬於上市公司股東淨利潤約1.34億元-1.51億元,同比增長140%-170%。業績變動原因如下:
1、受新型冠狀病毒疫情的影響,市場對公司產品需求大增,公司積極響應黨中央習近平總書記的重要指示,切實做好保障人民羣眾生命安全、身體健康及醫療的需要。在做好疫情防控的前提下全力以赴趕產,保障公司產品的供應,儘量滿足疫情及人民羣眾的用藥需求,疫情防控藥品及用品的銷量實現大幅增長,公司整體經營業績實現了快速增長;
2、報告期內,預計非經常性損益對淨利潤的影響金額約300萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.